Skip to main content
Erschienen in: BMC Oral Health 1/2020

Open Access 01.12.2020 | Research article

Differential expression of matrix metalloproteinases and miRNAs in the metastasis of oral squamous cell carcinoma

verfasst von: Zhen-Hu Ren, Kun Wu, Rong Yang, Zhe-Qi Liu, Wei Cao

Erschienen in: BMC Oral Health | Ausgabe 1/2020

Abstract

Background

Our study aimed to reveal the regulatory mechanisms of miRNAs and matrix metalloproteinases (MMPs) in oral squamous cell carcinoma (OSCC).

Methods

The mRNA and miRNA expression profiles of six metastatic tumour samples, six nonmetastatic tumour samples, and six normal tissue samples were used for microarray analysis. Moreover, the important genes and miRNAs were validated by published profiles in Oncomine and by qRT-PCR.

Results

MMP7, MMP13, and MMP10 were upregulated, and MMP12 and MMP9 were downregulated in metastatic tumours compared with nonmetastatic tumours. MMP7 was regulated by miR-4697-5p and miR-7109-5p. MMP7 and MMP13 were upregulated in OSCC samples compared with normal samples in Oncomine. Moreover, qRT-PCR revealed that the expression of miR-7109-5p and miR-34b was decreased in metastatic tumours compared with nonmetastatic tumours.

Conclusions

Our study suggested that miR-7109-5p and miR-34b might play important roles in the metastasis of OSCC by regulating MMP7 and MMP13 expression, respectively.
Hinweise
Zhen-Hu Ren and Kun Wu contributed equally to this work.
The abstract of this study has not been presented at any meetings regarding the research on the title page.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12903-020-1013-0.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AJCC/ UICC
American Joint Committee on Cancer/Union for International Cancer Control
DEGs
Differentially expressed genes
DE-miRNAs
Differentially expressed miRNAs
ECM
Extracellular matrix
EMT
Epithelial-mesenchymal transition
miRNAs
MicroRNAs
MMPs
Matrix metalloproteinases
OSCC
Oral squamous cell carcinoma

Background

Oral squamous cell carcinoma (OSCC) is one of the most common malignancies of the head and neck region in the world [1, 2]. OSCC is particularly risky and is usually discovered when the cancer has metastasized to the lymph nodes of the neck since it progresses without producing pain or symptoms that might be readily recognized by the patients in its early stages [3]. Although surgical resection followed by postoperative radiotherapy and/or chemotherapy has made considerable treatment progress, the 5-year overall survival rate of OSCC patients still remains poor due to the common neighbouring tissue invasion and neck lymph node metastasis [46]. Moreover, though many research groups have made great efforts to study OSCC pathogenesis, the underlying mechanisms of OSCC tumourigenesis and development have not been fully elucidated. Therefore, further studies focusing on the molecular mechanisms of OSCC are still urgently needed to improve early diagnosis, targeted therapy and prognosis.
Matrix metalloproteinases (MMPs) are a family of highly homologous extracellular zinc- and calcium-dependent endopeptidases with enzymatic activity and are capable of degrading many components from either the extracellular matrix (ECM) or basement membrane [7]. Studies have shown that MMPs are involved in numerous physiopathological processes, such as tissue remodelling, embryonic development, mammary involution, bone reabsorption, and wound healing [8, 9]. MMPs induced by both tumour cells and surrounding stromal cells are related to various processes associated with tumour cell proliferation, angiogenesis, neighbouring invasion and remote metastasis due to their ability to degrade ECM and alter cell migration [10, 11]. Increased levels of one or several MMPs have been found in most human cancers [12]. Overexpressed MMP-2 and MMP-9 are involved in the invasion process of OSCC, and MMP-9 is related to the poor prognosis of OSCC patients without neck node metastasis [13]. Significantly higher MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-10, MMP-11, and MMP-13 levels were found in tumours compared with normal mucosa, and MMP-9 might be useful for evaluating the malignant potential of head and neck squamous cell carcinoma [14]. It has also been reported that CXCR4 might promote OSCC cell migration and invasion by regulating MMP9 and MMP13 expression to activate the ERK signalling pathway [15]. Overall, increasing evidence has suggested that MMPs play critical roles in OSCC progression.
MicroRNAs (miRNAs) are a class of short noncoding RNAs that regulate the levels of posttranscriptional mRNAs by anchoring to the target sites on mRNA sequences in a complementary base-pairing manner [16, 17]. It has been reported that miR-222 inhibits OSCC cell invasion via the downregulation of MMP1 expression [18]. Moreover, miR-29a may play an inhibiting role in the progression of OSCC by negatively regulating MMP2 expression [19]. These findings provide important clues for potential therapeutic targets and approaches in the future. However, the miRNA regulatory mechanisms of MMP expression in OSCC metastasis remain unclear. Thus, the elucidation of aberrantly expressed MMPs and the related miRNA regulatory mechanisms in OSCC progression is critical.
In the present study, we aimed to reveal the possible regulatory mechanisms related to miRNAs and MMPs involved in the OSCC metastatic process. Samples collected from patients with nonmetastatic or metastatic tumours, as well as normal controls, were used for high-throughput mRNA and miRNA microarray analysis. The selected important markers involved in the metastatic process were also validated by experiments in another cohort of OSCC patients.

Methods

Patients and clinical tissue samples

Twenty-seven OSCC patients (14 with nonmetastatic tumours and 13 with metastatic tumours) were enrolled in our retrospective study. The tumours were diagnosed and staged according to the 8th edition of the AJCC/UICC cancer staging manual [20]. All patients underwent en bloc excision with primary tumour excision combined with neck dissection (bilateral neck dissection was performed if the tumour crossed the midline) in our hospital (Oral and Maxillofacial-Head and Neck Oncology Department, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine) between October 2016 and March 2017. The primary tumour site of metastatic OSCC, primary tumour site of nonmetastatic OSCC and paired normal oral mucosa outside the tumour 2 cm away belonged to the same anatomical site as the primary tumour and were collected during surgery (all tissues were cut with a steel knife and immediately snap-frozen in liquid nitrogen). The nonmetastatic patients did not have occult lymph node metastasis discovered postoperatively. The clinical and pathological characteristics of the enrolled patients are listed in Tables 1 and 2. The tumour samples collected from six metastatic OSCC patients (No. 1–6), as well as the tumour and paired adjacent normal tissue samples collected from six nonmetastatic OSCC patients (No. 7–12), were used for the microarray assay. The tumour samples from another eight nonmetastatic OSCC patients (No. 13–20) and seven metastatic OSCC patients (No. 21–27) were obtained for further experimental validation.
Table 1
Clinical characteristic of the oral squamous cell carcinoma (OSCC) patients used for microarray assay and qRT-PCR
NO.
Tumor statue
Age range (years)
Site
Clinical stage
TNM classification
Application
1
Nonmetastatic
40–49
Tongue
II
T2N0M0
Microarray assay
2
Nonmetastatic
60–69
Oral floor
III
T3N0M0
Microarray assay
3
Nonmetastatic
40–49
Tongue
II
T2N0M0
Microarray assay
4
Nonmetastatic
60–69
Gingiva
II
T2N0M0
Microarray assay
5
Nonmetastatic
40–49
Tongue
IV
T4N0M0
Microarray assay
6
Nonmetastatic
50–59
Buccal mucosa
III
T3N0M0
Microarray assay
7
Metastatic
50–59
Tongue
III
T2N1M0
Microarray assay
8
Metastatic
60–69
Tongue
IV
T2N2M0
Microarray assay
9
Metastatic
40–49
Tongue
IV
T1N2M0
Microarray assay
10
Metastatic
60–69
Tongue
IV
T2N2M0
Microarray assay
11
Metastatic
50–59
Tongue
IV
T2N2M0
Microarray assay
12
Metastatic
50–59
Buccal mucosa
IV
T1N2M0
Microarray assay
13
Nonmetastatic
50–59
Tongue
II
T2N0M0
qRT-PCR
14
Nonmetastatic
40–49
Tongue
II
T2N0M0
qRT-PCR
15
Nonmetastatic
60–69
Buccal mucosa
II
T2N0M0
qRT-PCR
16
Nonmetastatic
40–49
Gingiva
II
T2N0M0
qRT-PCR
17
Nonmetastatic
30–39
Tongue
II
T2N0M0
qRT-PCR
18
Nonmetastatic
60–69
Gingiva
III
T3N0M0
qRT-PCR
19
Nonmetastatic
70–79
Tongue
III
T3N0M0
qRT-PCR
20
Nonmetastatic
50–59
Tongue
IV
T4N0M0
qRT-PCR
21
Metastatic
50–59
Buccal mucosa
IV
T1N2M0
qRT-PCR
22
Metastatic
70–79
Tongue
IV
T2N2M0
qRT-PCR
23
Metastatic
60–69
Tongue
IV
T2N2M0
qRT-PCR
24
Metastatic
60–69
Tongue
IV
T2N2M0
qRT-PCR
25
Metastatic
50–59
Oral floor
IV
T1N2M0
qRT-PCR
26
Metastatic
50–59
Buccal mucosa
IV
T4N1M0
qRT-PCR
27
Metastatic
40–49
Tongue
IV
T3N1M0
qRT-PCR
TNM tumor, node metastasis
Table 2
Basic information was compared between the two groups
Group
nonmetastatic
metastatic
P
Age(y)
55.7
57.9
0.468
Gender
  
0.157
 Man
12
13
 
 Woman
2
0
 
Clinical stage
  
0.012
 II
8
0
 
 III
4
1
 
 IV
2
12
 
Tumor site
  
0.163
 Tongue
8
9
 
 Buccal
2
3
 
 Gingiva
3
0
 
 Oral floor
1
1
 
The retrospective study was approved by the Scientific Research Projects Approval Determination of Independent Ethics Committee of Shanghai Ninth People’s Hospital affiliated with Shanghai Jiao Tong University. Informed consent was obtained from all subjects before the samples were collected during surgery.

Total RNA isolation and microarray processing

Total RNA was extracted from the metastatic tumour, nonmetastatic tumour and normal control tissue samples using TRIzol reagent (Invitrogen, USA) according to the manufacturer’s protocol. Afterwards, the extracted RNA was purified by a Total Tissue RNA Purification Kit (Qiagen Inc., Valencia, CA, USA). The RNA concentrations were measured by a NanoDrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Denaturing gel electrophoresis was used to examine the purity and integrity of the total RNA extracted from the tissue samples.
The qualified total RNA was used to synthetize first-strand cDNA using a cDNA synthesis kit (TIANGEN, China), followed by fluorescent labelling with Agilent’s Low Input Quick Amp WT Labeling kit (Agilent Technologies, USA) according to the manufacturer’s instructions. The labelled cDNA was purified with an RNeasy Mini kit (Qiagen, Germany) and hybridized onto the Agilent Human SurePrint G3 Human GE 8 × 60 k v16 microarray chip (Agilent Technologies, USA) [21] by Shanghai OE Biotech Company (Shanghai, China). Total RNA was also used for the miRNA microarray experiment. The miRNA molecules in total RNA were labelled with the Agilent miRNA labeling reagent and hybridized onto the Agilent Human SurePrint G3 8 × 60 k v16 miRNA microarray chip (Agilent Technologies, USA) according to the manufacturer’s protocol. After hybridization, the samples were scanned by an Agilent Microarray Scanner (Agilent Technologies, USA), and raw data were obtained by using feature extraction software (Agilent Technologies, USA). GeneSpring GX 12.6 software (Agilent Technologies, USA) was used to normalize the obtained raw data.

Microarray data analysis

The limma (Linear Models for Microarray Analysis) [22] package in R was used to perform differential expression analysis. The thresholds for differentially expressed genes (DEGs) and differentially expressed miRNAs (DE-miRNAs) were set as |log2 fold-change (FC)| > 0.5 and p-value < 0.05. Moreover, the expression values of screened MMP-related DEGs and DE-miRNAs were hierarchically clustered by the pheatmap package [23] in R based on the encyclopaedia of distances [24] to observe the differences in expression levels intuitively.
The target genes of the differentially regulated miRNAs were predicted by TargetScan (http://​www.​targetscan.​org/​vert_​71/​) [25], miRDB (http://​mirdb.​org) [26], miRTarBase (http://​mirtarbase.​mbc.​nctu.​edu.​tw/​) [27], and TarBase (http://www.microrna.gr/tarbase) [28]. The miRNA-mRNA regulatory relationships involved with MMPs were selected to construct the MMP-related regulatory network via Cytoscape (http://​www.​cytoscape.​org/​) [29]. Furthermore, we used Oncomine (http://​www.​oncomine.​org) to reveal the expression of important genes in the available microarray data comparing OSCCsamples with normal samples.

Gene ontology (GO) functional and pathway enrichment analysis

The GO functions in terms of the biological process (BP), molecular function (MF), and cellular component (CC) categories for the MMP-related DEGs and target genes of DE-miRNAs were enriched through the Database for Annotation, Visualization and Integrated Discovery (DAVID) [30]. The potential pathways of these MMP-related DEGs and target genes were also revealed by Kyoto Encyclopedia of Genes and Genomes (KEGG) and Orthology-Based Annotation System (KOBAS) [31]. The cutoff criterion was set as p-value < 0.05.

Quantitative real-time RT-PCR (qRT-PCR)

Total RNA was extracted with TRIzol Reagent (Invitrogen, USA), and cDNA was synthesized using the miRcute Plus miRNA First-Strand cDNA Synthesis Kit (TIANGEN, China). All real-time qPCR reactions were performed using an ABI StepOne Real-time PCR system (Life Technologies, USA) and the miRcute Plus miRNA qPCR kit (TIANGEN, China). The threshold cycle calculation of each miRNA was performed with SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA). The samples with undetermined Ct values (Ct > 40) for the control were excluded from analysis. The fold change was assessed using the 2-ΔΔCt method. The relative expression of the miRNAs was normalized using U6 as an endogenous control. Two-sample t test was used to compare the normalized expression levels between the two groups. A p-value < 0.05 was considered a statistically significant difference.

Results

We screened the MMP-related DEGs in metastatic tumour samples (M vs N) or nonmetastatic tumour samples (P vs N) compared to normal controls and in metastatic tumour samples compared to nonmetastatic cancer samples (M vs P) (Fig. 1a). A total of 13 MMP-related DEGs were identified. Ten MMP family members (MMP12, MMP15, MMP1, MMP9, MMP7, MMP3, MMP14, MMP13, MMP10, and MMP8) were upregulated and one was downregulated (MMP27) in nonmetastatic tumour samples compared with normal controls. Ten MMP family members (MMP12, MMP1, MMP9, MMP7, MMP3, MMP14, MMP13, MMP17, MMP10, and MMP11) were upregulated and one was downregulated (MMP27) in metastatic tumour samples compared with normal controls. MMP7, MMP13, and MMP10 were significantly upregulated, while MMP12 and MMP9 were downregulated in metastatic tumour samples compared with nonmetastatic tumour samples. Hierarchical clustering analysis showed that the gene expression profiles were significantly different among nonmetastatic tumour samples, metastatic tumour samples, and normal tissues (Fig. 1) (details in the Additional file 1).
According to the differential expression analysis, a total of 111 DE-miRNAs were identified. There were 81 significantly dysregulated miRNAs (35 downregulated and 46 upregulated DE-miRNAs) between nonmetastatic tumour and normal samples (P vs N), 50 significantly dysregulated miRNAs (33 downregulated and 18 upregulated DE-miRNAs) between metastatic tumour and normal samples (M vs N), and 7 significantly dysregulated miRNAs (6 downregulated and 1 upregulated DE-miRNAs) between metastatic and nonmetastatic tumour samples (M vs P) (Fig. 2a). Hierarchical clustering showed obvious miRNA expression differences among nonmetastatic tumour samples, metastatic tumour samples, and normal tissues (Fig. 2b).

Functional and pathway enrichment analysis

Functional enrichment analysis of the MMP-related DEGs revealed that these genes were notably involved with 38, 4 and 11 GO terms in the BP, CC and MF categories, respectively (Table 3). These functions were mainly involved in the collagen catabolic process (P < 0.0001), extracellular matrix disassembly (P < 0.0001), extracellular matrix (P < 0.0001), and metalloendopeptidase activity (P < 0.0001). The three significantly enriched KEGG pathways were bladder cancer, rheumatoid arthritis and pathways in cancer (Table 4).
Table 3
The Gene Ontology (GO) functional enrichment analysis in terms of biology process (BP), cellular component (CC), molecular function (MF) for the MMP-related differentially expressed genes (DEGs)
Category
GO_ID
Term
P value
Count
Genes
BP
GO:0030574
collagen catabolic process
2.583e-24
11
MMP7, MMP14, MMP13, MMP1, MMP3, MMP8, MMP9, MMP12, MMP10, MMP11, MMP15
GO:0032963
collagen metabolic process
2.654e-22
11
MMP7, MMP14, MMP13, MMP1, MMP3, MMP8, MMP9, MMP12, MMP10, MMP11, MMP15
GO:0044259
multicellular organismal macromolecule metabolic process
4.247e-22
11
MMP7, MMP14, MMP13, MMP1, MMP3, MMP8, MMP9, MMP12, MMP11, MMP10, MMP15
GO:0022617
extracellular matrix disassembly
1.031e-21
11
MMP7, MMP13, MMP3, MMP12, MMP10, MMP15, MMP14, MMP1, MMP8, MMP9, MMP11
GO:0044236
multicellular organismal metabolic process
1.445e-21
11
MMP7, MMP13, MMP3, MMP12, MMP10, MMP15, MMP14, MMP1, MMP8, MMP9, MMP11
GO:0030198
extracellular matrix organization
1.668e-16
11
MMP7, MMP12, MMP10, MMP15, MMP14, MMP8, MMP13, MMP3, MMP1, MMP9, MMP11
GO:0043062
extracellular structure organization
1.720e-16
11
MMP7, MMP12, MMP10, MMP15, MMP14, MMP8, MMP13, MMP3, MMP1, MMP9, MMP11
GO:0006508
proteolysis
3.499e-11
12
MMP7, MMP12, MMP10, MMP14, MMP17, MMP15, MMP13, MMP3, MMP8, MMP9, MMP11, MMP1
GO:0035987
endodermal cell differentiation
3.661e-10
4
MMP9, MMP14, MMP15, MMP8
GO:0001706
endoderm formation
1.064e-09
4
MMP9, MMP14, MMP15, MMP8
CC
GO:0031012
extracellular matrix
1.486e-17
12
MMP7, MMP12, MMP10, MMP15, MMP14, MMP8, MMP13, MMP3, MMP1, MMP17, MMP9, MMP11
GO:0005578
proteinaceous extracellular matrix
4.500e-15
10
MMP7, MMP12, MMP10, MMP8, MMP13, MMP3, MMP1, MMP17, MMP9, MMP11
GO:0005615
extracellular space
7.395e-05
6
MMP7, MMP10, MMP13, MMP3, MMP8, MMP9
GO:0005576
extracellular region
4.364e-04
10
MMP10, MMP11, MMP7, MMP17, MMP8, MMP9, MMP3, MMP12, MMP13, MMP1
MF
GO:0004222
metalloendopeptidase activity
5.214e-25
12
MMP7, MMP14, MMP13, MMP1, MMP3, MMP17, MMP8, MMP9, MMP12, MMP11, MMP10, MMP15
GO:0008237
metallopeptidase activity
4.690e-22
12
MMP7, MMP13, MMP3, MMP12, MMP10, MMP15, MMP14, MMP1, MMP8, MMP17, MMP9, MMP11
GO:0004175
endopeptidase activity
7.643e-18
12
MMP7, MMP12, MMP10, MMP15, MMP14, MMP8, MMP13, MMP3, MMP1, MMP17, MMP9, MMP11
GO:0008233
peptidase activity
1.534e-15
12
MMP7, MMP12, MMP10, MMP14, MMP8, MMP17, MMP9, MMP11, MMP15, MMP13, MMP3, MMP1
GO:0005509
calcium ion binding
4.088e-12
10
MMP12, MMP10, MMP14, MMP8, MMP17, MMP11, MMP15, MMP13, MMP3, MMP1
GO:0008270
zinc ion binding
4.449e-12
12
MMP7, MMP12, MMP10, MMP14, MMP17, MMP15, MMP13, MMP3, MMP8, MMP9, MMP11, MMP1
GO:0046914
transition metal ion binding
4.452e-11
12
MMP7, MMP12, MMP10, MMP14, MMP17, MMP15, MMP13, MMP3, MMP8, MMP9, MMP11, MMP1
GO:0016787
hydrolase activity
2.326e-08
12
MMP10, MMP14, MMP15, MMP3, MMP11, MMP7, MMP12, MMP17, MMP13, MMP8, MMP9, MMP1
GO:0046872
metal ion binding
7.714e-06
12
MMP10, MMP14, MMP15, MMP3, MMP11, MMP7, MMP12, MMP17, MMP13, MMP8, MMP9, MMP1
GO:0043169
cation binding
9.747e-06
12
MMP10, MMP11, MMP7, MMP17, MMP8, MMP9, MMP14, MMP15, MMP3, MMP12, MMP13, MMP1
GO:0003824
catalytic activity
1.878e-04
12
MMP10, MMP11, MMP7, MMP17, MMP8, MMP9, MMP14, MMP15, MMP3, MMP12, MMP13, MMP1
Note: only the top 10 functions related to biology process were shown
Table 4
The enriched KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways for MMP-related DEGs
Pathway ID
Description
Count
Genes
P Value
hsa05219
Bladder cancer
2
MMP1, MMP9
3.863e-05
hsa05323
Rheumatoid arthritis
2
MMP3, MMP1
3.837e-04
The target genes of the three comparison groups of differentially expressed miRNAs were also used to perform functional and pathway enrichment analysis. The target genes of the DE-miRNAs identified in nonmetastatic tumour samples compared to normal controls were mainly enriched in proline transport, cerebral cortex tangential migration, cargo loading into vesicles and endocytosis (Fig. 3a). The target genes of the DE-miRNAs identified in metastatic tumour samples compared to normal controls were mainly enriched in the negative regulation of cAMP-dependent protein kinase activity, cAMP-dependent protein kinase inhibitor activity, and endocytosis (Fig. 3b). The target genes of the DE-miRNAs identified in metastatic tumour samples compared to nonmetastatic tumour samples were mainly enriched in organelle membrane contact site, cell migration in hindbrain, Wnt signalling pathway, TGF-beta signalling pathway, MAPK signalling pathway, and endocytosis (Fig. 3c).

Construction of the MMP-related regulatory network

The target genes of the DE-miRNAs were predicted, and the relationships related to MMPs were selected for regulatory network construction. The regulatory network involved 55 DE-miRNAs and 12 MMP-related DEGs (Fig. 4). MMP7 was regulated by miR-4697-5p and miR-7109-5p. MMP13 was regulated by 10 DE-miRNAs (miR-4697-5p, miR-6826-5p, miR-6741-5p, miR-6793-5p, miR-34b, miR-6759-3p, miR-503-5p, miR-6753-3p, miR-7111-3p, and miR-129-1-3p). MMP10 was the target gene of miR-20b-5p and miR-6768-5p. MMP12 was regulated by miR-6090, and MMP9 was regulated by 5 DE-miRNAs (miR-619-5p, miR-3646, miR-4750-3p, miR-4516, and miR-7114-3p) (Table 5).
Table 5
The MMP-related DEGs and DE-miRNAs in the constructed regulatory network
MMP-related DEGs
Degree
DE-miRNAs
MMP12
1
miR-6090
MMP10
2
miR-20b-5p, miR-6768-5p
MMP7
2
miR-4697-5p, miR-7109-5p
MMP17
3
miR-3198, miR-6741-5p, miR-6753-3p
MMP1
5
miR-21-3p, miR-6759-3p, miR-185-5p, miR-331-3p, miR-3651
MMP9
5
miR-619-5p, miR-3646, miR-4750-3p, miR-4516, miR-7114-3p
MMP3
7
miR-20a-5p, miR-31-5p, miR-17-5, miR-18b-5p, miR-572, miR-6768-5p, miR-548q
MMP11
8
miR-20a-5p, miR-17-5p, miR-103a-3p, miR-4728-3p, miR-20b-5p, miR-7845-5p, miR-129-1-3p, miR-4476
MMP13
10
miR-4697-5p, miR-6826-5p, miR-6741-5p, miR-6793-5p, miR-34b-5p, miR-6759-3p, miR-503-5p, miR-6753-3p, miR-7111-3p, miR-129-1-3p
MMP15
11
miR-619-5p, miR-3198, miR-3180-3p, miR-15b-5p, miR-7109-5p, miR-10b-5p, miR-199b-5p, miR-1227-5p, miR-6076, miR-548q, miR-7114-3p
MMP14
14
miR-6132, miR-4485-5pmiR-103a-3pmiR-6741-5p, miR-6793-5p, miR-4253, miR-154-5p, miR-1227-5p, miR-6753-3p, miR-4324, miR-6076, miR-4516, miR-7114-3p, miR-4687-3p
MMP8
15
miR-3652, miR-3663-5p, miR-142-3p, miR-486-5p, miR-6746-5p, miR-99a-5p, miR-331-3p, miR-154-5p, miR-99b-3p, miR-299-5p, miR-1227-5p, miR-7111-3p, miR-129-1-3p, miR-4687-3p, miR-100-5p
Note: the miRNA names in red color are validated using qRT-PCR

Validation by data mining and qRT-PCR

The expression levels of MMP7 (P < 0.0001), MMP13 (P < 0.0001) and MMP10 (P < 0.0001) were also significantly higher in OSCC samples than in normal samples by data mining of published profiles in Oncomine (http://​www.​oncomine.​org) (Fig. 5a). The expression levels of MMP7, MMP13, MMP10, miR-7109-5p and miR-34b in nonmetastatic cancer samples and metastatic cancer samples were measured by qRT-PCR. The expression levels of MMP7 (P = 0.0123) and MMP13 (P = 0.0147) were significantly increased in the metastatic tumour samples, while that of MMP10 (P = 0.0932) was not (Fig. 5b). The expression levels of both miR-7109-5p (P = 0.0233) and miR-34b (P = 0.0146) were decreased in metastatic tumour samples compared with nonmetastatic tumour samples (Fig. 5c).

Discussion

In our study, mRNA and miRNA microarrays were used to analyse the expression profiles of MMPs and miRNAs in nonmetastatic tumour samples, metastatic tumour samples, and normal tissues. The results showed that 10 MMP genes were upregulated and MMP27 was downregulated in nonmetastatic tumour samples compared with normal controls. MMP12, MMP1, MMP9, MMP7, MMP3, MMP14, MMP17, MMP13, and MMP10 were the 9 common upregulated genes in metastatic and nonmetastatic tumour samples compared with the normal controls. Moreover, MMP7, MMP13, and MMP10 were significantly upregulated in metastatic tumour samples compared with nonmetastatic tumour samples.
Deraz et al. [32] revealed that the overexpression of MMP-10 could promote the invasion and metastasis of head and neck squamous cell carcinoma, and invasion driven by MMP-10 is possibly associated with p38 MAPK inhibition. It has been reported that MMP-13 could promote the invasion, migration, and adhesion abilities of oral cancer cells [33]. The abnormal expression of MMP-7 has been found to be closely related to the biological behaviour of OSCC, and MMP-7 may be induced by COX-2 to contribute to the invasion and metastasis of OSCC [34]. The upregulation of glutamate decarboxylase 1 (GAD1) correlated with cellular invasiveness and migration in OSCC by regulating β-catenin translocation and MMP7 activation [35]. Functional enrichment analysis revealed that MMP7, MMP13, and MMP10 were related to the collagen catabolic process, extracellular matrix disassembly, extracellular matrix, and metalloendopeptidase activity. Therefore, the overexpression of MMP7, MMP13, and MMP10 might play important roles in controlling tumoural invasiveness and metastasis in OSCC.
The expression levels of MMP7, MMP13 and MMP10 were validated to be significantly upregulated in oral cancer compared with normal samples according to the data mining of published profiles in Oncomine. Among these differentially expressed MMPs, we focused on the roles of MMP7, MMP13 and MMP10. After the target genes of the DE-miRNAs were predicted, functional enrichment analysis showed that the target genes of the DE-miRNAs identified in metastatic tumour samples compared to nonmetastatic tumour samples were mainly enriched in organelle membrane contact sites, cell migration in the hindbrain, and the TGF-beta signalling pathway. TGF-β1-triggered epithelial-mesenchymal transition (EMT) may play important roles in OSCC progression by upregulating MMPs to promote EMT [36]. Thus, the identified DE-miRNAs might be important for the progression of OSCC by regulating the target gene levels to influence the TGF-beta signalling pathway.
In our study, the regulatory relationships related to MMPs were selected to construct a regulatory network. In the regulatory network, MMP7 was regulated by miR-4697-5p and miR-7109-5p. MMP13 was regulated by 10 DE-miRNAs (miR-4697-5p, miR-6826-5p, miR-6741-5p, miR-6793-5p, miR-34b, miR-6759-3p, miR-503-5p, miR-6753-3p, miR-7111-3p, and miR-129-1-3p). Moreover, qRT-PCR confirmed that the expression of miR-7109-5p and miR-34b was significantly downregulated in metastatic OSCC samples compared with nonmetastatic tumour samples using samples collected from another cohort of OSCC patients. The abnormal expression of miR-7109-5p has been reported to occur in breast cancer and is associated with cancer development in patients with chronic obstructive pulmonary disease [37, 38]. The reduced expression of miR-34b and miR-129-3p was observed in gastric cancers due to DNA hypermethylation and was associated with poor clinicopathological features [39]. It was also suggested that the reduced expression of miR-34b*/c may be particularly important for the progression to the most advanced stages of human epithelial ovarian cancer [40]. Low expression levels of miR-34b and miR-34c were associated with distant metastasis formation in lung cancer [41]. To our knowledge, few studies have reported the regulatory mechanisms of miR-7109-5p and miR-34b in OSCC. According to the results of our study, miR-7109-5p and miR-34b seem to have tumour suppressor functions in OSCC. The aggressive form of OSCC shows the downregulation of these two miRNAs and subsequent upregulation of MMP 7 and MMP13, which are normally inhibited by miR-7109-5p and miR-34b. The feasibility of miR-7109-5p and miR-34b as promising prognostic and diagnostic indicators or potential cancer therapeutic targets will be evaluated in further studies. In the future, we will focus on the interaction of miRNAs and MMPs and the mechanism of OSCC progression mediated by the miRNA axis to provide valuable strategies for the diagnosis, treatment and prognosis of OSCC.
Several limitations of this study should be addressed. The most important limitation in this regard is the limited number of study samples and inability to control for potential confounders. Another limitation is that the patients included in this study had varying T and N stages, and the two groups of cases were not selected in pairs. The homogeneity of the two groups of cases was different. The metastatic group appears to be more homogeneous than the nonmetastatic group. The results of this study are at the transcriptional level, and further experiments at the protein level are needed to verify the results of this experiment.

Conclusion

In conclusion, our study performed gene and miRNA microarray analysis to reveal the underlying regulatory mechanisms of miRNAs and MMPs involved in the OSCC metastatic process. The MMP-related DEGs and DE-miRNAs were identified among the nonmetastatic tumour samples, metastatic tumour samples, and normal tissues. MMP7, MMP13, and MMP10 were upregulated in metastatic tumours compared with nonmetastatic tumours. The reduced expression of miR-7109-5p and miR-34b might play important roles in the metastasis of OSCC by upregulating MMP7 and MMP13, respectively.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12903-020-1013-0.

Acknowledgements

Not applicable.
This study was approved by the Scientific Research Projects Approval Determination of Independent Ethics Committee of Shanghai Ninth People’s Hospital affiliated with Shanghai Jiao Tong University. Informed consent (written) was obtained from all patients before the samples were collected during surgery.
The patients signed an informed consent form agreeing with the publication of this study.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Chen W, Zheng R, Zuo T, Zeng H, Zhang S, He J. National cancer incidence and mortality in China, 2012. Chin J Cancer Res. 2016;28(1):1–11.PubMedPubMedCentral Chen W, Zheng R, Zuo T, Zeng H, Zhang S, He J. National cancer incidence and mortality in China, 2012. Chin J Cancer Res. 2016;28(1):1–11.PubMedPubMedCentral
2.
3.
Zurück zum Zitat Severino P, Oliveira LS, Andreghetto FM, Torres N, Curioni O, Cury PM, Toporcov TN, Paschoal AR, Durham AM. Small RNAs in metastatic and non-metastatic oral squamous cell carcinoma. BMC Med Genet. 2015;8(1):1–15. Severino P, Oliveira LS, Andreghetto FM, Torres N, Curioni O, Cury PM, Toporcov TN, Paschoal AR, Durham AM. Small RNAs in metastatic and non-metastatic oral squamous cell carcinoma. BMC Med Genet. 2015;8(1):1–15.
4.
Zurück zum Zitat Lin CW, Yang WE, Lee WJ, Hua KT, Hsieh FK, Hsiao M, Chen CC, Chow JM, Chen MK, Yang SF, et al. Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis. Carcinogenesis. 2016;37(7):712–22.PubMedCrossRef Lin CW, Yang WE, Lee WJ, Hua KT, Hsieh FK, Hsiao M, Chen CC, Chow JM, Chen MK, Yang SF, et al. Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis. Carcinogenesis. 2016;37(7):712–22.PubMedCrossRef
5.
Zurück zum Zitat Ren ZH, Xu JL, Li B, Fan TF, Ji T, Zhang CP. Elective versus therapeutic neck dissection in node-negative oral cancer: evidence from five randomized controlled trials. Oral Oncol. 2015;51(11):976–81.PubMedCrossRef Ren ZH, Xu JL, Li B, Fan TF, Ji T, Zhang CP. Elective versus therapeutic neck dissection in node-negative oral cancer: evidence from five randomized controlled trials. Oral Oncol. 2015;51(11):976–81.PubMedCrossRef
6.
Zurück zum Zitat Ren ZH, Gong ZJ, Wu HJ. Unit resection of buccal squamous cell carcinoma: description of a new surgical technique. Oncotarget. 2017;8(32):52420–31.PubMedCrossRef Ren ZH, Gong ZJ, Wu HJ. Unit resection of buccal squamous cell carcinoma: description of a new surgical technique. Oncotarget. 2017;8(32):52420–31.PubMedCrossRef
7.
Zurück zum Zitat Munchow EA, Bottino MC. Recent advances in adhesive bonding - the role of biomolecules, Nanocompounds, and bonding strategies in enhancing resin bonding to dental substrates. Curr Oral Health Rep. 2017;4(3):215–27.PubMedPubMedCentralCrossRef Munchow EA, Bottino MC. Recent advances in adhesive bonding - the role of biomolecules, Nanocompounds, and bonding strategies in enhancing resin bonding to dental substrates. Curr Oral Health Rep. 2017;4(3):215–27.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Asp Med. 2008;29(5):290–308.CrossRef Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Asp Med. 2008;29(5):290–308.CrossRef
10.
Zurück zum Zitat Blanco-Prieto S, Barcia-Castro L, Paez de la Cadena M, Rodriguez-Berrocal FJ, Vazquez-Iglesias L, Botana-Rial MI, Fernandez-Villar A, De Chiara L. Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis. BMC Cancer. 2017;17(1):823.PubMedPubMedCentralCrossRef Blanco-Prieto S, Barcia-Castro L, Paez de la Cadena M, Rodriguez-Berrocal FJ, Vazquez-Iglesias L, Botana-Rial MI, Fernandez-Villar A, De Chiara L. Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis. BMC Cancer. 2017;17(1):823.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Moro N, Mauch C, Zigrino P. Metalloproteinases in melanoma. Eur J Cell Biol. 2014;93(1–2):23–9.PubMedCrossRef Moro N, Mauch C, Zigrino P. Metalloproteinases in melanoma. Eur J Cell Biol. 2014;93(1–2):23–9.PubMedCrossRef
13.
Zurück zum Zitat de Vicente JC, Fresno MF, Villalain L, Vega JA, Hernández VG. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol. 2005;41(3):283–93.PubMedCrossRef de Vicente JC, Fresno MF, Villalain L, Vega JA, Hernández VG. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol. 2005;41(3):283–93.PubMedCrossRef
14.
Zurück zum Zitat Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2001;127(7):813.PubMed Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2001;127(7):813.PubMed
15.
Zurück zum Zitat Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res. 2011;9(2):161.PubMedCrossRef Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res. 2011;9(2):161.PubMedCrossRef
17.
Zurück zum Zitat Chekulaeva M, Filipowicz W. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol. 2009;21(3):452–60.PubMedCrossRef Chekulaeva M, Filipowicz W. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol. 2009;21(3):452–60.PubMedCrossRef
18.
Zurück zum Zitat Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H, Zhou X. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics. 2009;6(3):131–9.PubMed Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H, Zhou X. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics. 2009;6(3):131–9.PubMed
19.
Zurück zum Zitat Le L, Xiaofeng X, Jing L, Yang G, Zhenghui X, Haiping Z, Wei J, Weijian S, Qiaoming Z. MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomed Pharmacother. 2014;68(1):13–9.CrossRef Le L, Xiaofeng X, Jing L, Yang G, Zhenghui X, Haiping Z, Wei J, Weijian S, Qiaoming Z. MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomed Pharmacother. 2014;68(1):13–9.CrossRef
20.
Zurück zum Zitat Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.PubMedCrossRef Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.PubMedCrossRef
21.
Zurück zum Zitat Fan T, Chen J, Zhang L, Gao P, Hui Y, Xu P, Zhang X, Liu H. Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway. Mol Cancer. 2016;15:23.PubMedPubMedCentralCrossRef Fan T, Chen J, Zhang L, Gao P, Hui Y, Xu P, Zhang X, Liu H. Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway. Mol Cancer. 2016;15:23.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.PubMedPubMedCentralCrossRef Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng Z, Zhu G, Qi J, Ma H, Nian H, et al. RNA-seq analyses of multiple meristems of soybean: novel and alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 2014;14:169.PubMedPubMedCentralCrossRef Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng Z, Zhu G, Qi J, Ma H, Nian H, et al. RNA-seq analyses of multiple meristems of soybean: novel and alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 2014;14:169.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Gosling C. Encyclopedia of distances. Ref Rev. 2009;24(6):1–583. Gosling C. Encyclopedia of distances. Ref Rev. 2009;24(6):1–583.
25.
Zurück zum Zitat Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife Sciences. 2015;4:e05005. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife Sciences. 2015;4:e05005.
26.
27.
Zurück zum Zitat Sheng-Da H, Feng-Mao L, Wei-Yun W, Chao L, Wei-Chih H, Wen-Ling C, Wen-Ting T, Goun-Zhou C, Chia-Jung L, Chih-Min C. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011;39(Database issue):D163. Sheng-Da H, Feng-Mao L, Wei-Yun W, Chao L, Wei-Chih H, Wen-Ling C, Wen-Ting T, Goun-Zhou C, Chia-Jung L, Chih-Min C. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011;39(Database issue):D163.
28.
Zurück zum Zitat Sethupathy P, Corda BHatzigeorgiou AG. TarBase: a comprehensive database of experimentally supported animal microRNA targets. RNA. 2006;12(2):192–7.PubMedPubMedCentralCrossRef Sethupathy P, Corda BHatzigeorgiou AG. TarBase: a comprehensive database of experimentally supported animal microRNA targets. RNA. 2006;12(2):192–7.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC, Lempicki RA. The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007;8(9):R183.PubMedPubMedCentralCrossRef Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC, Lempicki RA. The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007;8(9):R183.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Wu J, Mao X, Cai T, Luo J, Wei L. KOBAS server: a web-based platform for automated annotation and pathway identification. Nucleic Acids Res. 2006;34(Web Server issue):W720–4.PubMedPubMedCentralCrossRef Wu J, Mao X, Cai T, Luo J, Wei L. KOBAS server: a web-based platform for automated annotation and pathway identification. Nucleic Acids Res. 2006;34(Web Server issue):W720–4.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Deraz EM, Kudo Y, Yoshida M, Obayashi M, Tsunematsu T, Tani H, Siriwardena SB, Keikhaee MR, Qi G, Iizuka S, et al. MMP-10/stromelysin-2 promotes invasion of head and neck cancer. PLoS One. 2011;6(10):e25438.PubMedPubMedCentralCrossRef Deraz EM, Kudo Y, Yoshida M, Obayashi M, Tsunematsu T, Tani H, Siriwardena SB, Keikhaee MR, Qi G, Iizuka S, et al. MMP-10/stromelysin-2 promotes invasion of head and neck cancer. PLoS One. 2011;6(10):e25438.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Huang SH, Law CH, Kuo PH, Hu RY, Yang CC, Chung TW, Li JM, Lin LH, Liu YC, Liao EC, et al. MMP-13 is involved in oral cancer cell metastasis. Oncotarget. 2016;7(13):17144–61.PubMedPubMedCentral Huang SH, Law CH, Kuo PH, Hu RY, Yang CC, Chung TW, Li JM, Lin LH, Liu YC, Liao EC, et al. MMP-13 is involved in oral cancer cell metastasis. Oncotarget. 2016;7(13):17144–61.PubMedPubMedCentral
34.
Zurück zum Zitat Li T-J, Cui J. COX-2, MMP-7 expression in oral lichen planus and oral squamous cell carcinoma. Asian Pac J Trop Med. 2013;6(8):640–3.PubMedCrossRef Li T-J, Cui J. COX-2, MMP-7 expression in oral lichen planus and oral squamous cell carcinoma. Asian Pac J Trop Med. 2013;6(8):640–3.PubMedCrossRef
35.
Zurück zum Zitat Kimura R, Kasamatsu A, Koyama T, Fukumoto C, Kouzu Y, Higo M, Endo-Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H, et al. Glutamate acid decarboxylase 1 promotes metastasis of human oral cancer by β-catenin translocation and MMP7 activation. BMC Cancer. 2013;13(1):555.PubMedPubMedCentralCrossRef Kimura R, Kasamatsu A, Koyama T, Fukumoto C, Kouzu Y, Higo M, Endo-Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H, et al. Glutamate acid decarboxylase 1 promotes metastasis of human oral cancer by β-catenin translocation and MMP7 activation. BMC Cancer. 2013;13(1):555.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Qiao B, Johnson NW, Gao J. Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta1 is snail family-dependent and correlates with matrix metalloproteinase-2 and -9 expressions. Int J Oncol. 2010;37(3):663.PubMed Qiao B, Johnson NW, Gao J. Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta1 is snail family-dependent and correlates with matrix metalloproteinase-2 and -9 expressions. Int J Oncol. 2010;37(3):663.PubMed
37.
Zurück zum Zitat Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, Backes C, Vogelmeier C, Diener C, Biertz F, Herr C, et al. Genome-wide MicroRNA expression profiles in COPD: early predictors for Cancer development. Genomics Proteomics Bioinformatics. 2018;16(3):162–71.PubMedPubMedCentralCrossRef Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, Backes C, Vogelmeier C, Diener C, Biertz F, Herr C, et al. Genome-wide MicroRNA expression profiles in COPD: early predictors for Cancer development. Genomics Proteomics Bioinformatics. 2018;16(3):162–71.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Kumar SGS, Kumar V, et al. Identification of key miRNA biomarkers by miRNA-gene interactions network regulating breast cancer in human. Asian J Pharm Pharmacol. 2018;4(5):608–14.CrossRef Kumar SGS, Kumar V, et al. Identification of key miRNA biomarkers by miRNA-gene interactions network regulating breast cancer in human. Asian J Pharm Pharmacol. 2018;4(5):608–14.CrossRef
39.
Zurück zum Zitat Tsai K-W, Wu C-W, Hu L-Y, Li S-C, Liao Y-L, Lai C-H, Kao H-W, Fang W-L, Huang K-H, Chan W-C, et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer. 2011;129(11):2600–10.PubMedCrossRef Tsai K-W, Wu C-W, Hu L-Y, Li S-C, Liao Y-L, Lai C-H, Kao H-W, Fang W-L, Huang K-H, Chan W-C, et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer. 2011;129(11):2600–10.PubMedCrossRef
40.
Zurück zum Zitat Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010;16(4):1119–28.PubMedPubMedCentralCrossRef Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010;16(4):1119–28.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Daugaard I, Knudsen A, Kjeldsen TE, Hager H, Hansen LL. The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma. Exp Mol Pathol. 2017;102(3):484–91.PubMedCrossRef Daugaard I, Knudsen A, Kjeldsen TE, Hager H, Hansen LL. The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma. Exp Mol Pathol. 2017;102(3):484–91.PubMedCrossRef
Metadaten
Titel
Differential expression of matrix metalloproteinases and miRNAs in the metastasis of oral squamous cell carcinoma
verfasst von
Zhen-Hu Ren
Kun Wu
Rong Yang
Zhe-Qi Liu
Wei Cao
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Oral Health / Ausgabe 1/2020
Elektronische ISSN: 1472-6831
DOI
https://doi.org/10.1186/s12903-020-1013-0

Weitere Artikel der Ausgabe 1/2020

BMC Oral Health 1/2020 Zur Ausgabe

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 Vorhofflimmern Nachrichten

Werden Personen mit Vorhofflimmern in der Blanking-Periode nach einer Katheterablation gegen eine bestehende Parodontitis behandelt, verbessert dies die Erfolgsaussichten. Dafür sprechen die Resultate einer prospektiven Untersuchung.

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

11.04.2024 Endokarditis Nachrichten

Bei welchen Personen eine Antibiotikaprophylaxe zur Prävention einer infektiösen Endokarditis nach invasiven zahnärztlichen Eingriffen sinnvoll ist, wird diskutiert. Neue Daten stehen im Einklang mit den europäischen Leitlinienempfehlungen.

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

08.04.2024 Zahnmedizin Nachrichten

Der Aufbau von Geweben und Organen während der Embryonalentwicklung wird von den Zellen bemerkenswert choreografiert. Für diesen Prozess braucht es spezielle sogenannte „Organisatoren“. In einer aktuellen Veröffentlichung im Fachjournal Nature Cell Biology berichten Forschende durch welchen Vorgang diese Organisatoren im Gewebe entstehen und wie sie dann die Bildung von Zähnen orchestrieren.

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

11.03.2024 Kinderzahnmedizin Nachrichten

Infolge der Umbenennung der Deutschen Gesellschaft für Kinderzahnheilkunde in Deutsche Gesellschaft für Kinderzahnmedizin (DGKiZ) wird deren Mitgliederzeitschrift Oralprophylaxe & Kinderzahnheilkunde in Oralprophylaxe & Kinderzahnmedizin umbenannt. Aus diesem Grunde trägt die erste Ausgabe in 2024 erstmalig den neuen Titel.

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Zahnmedizin und bleiben Sie gut informiert – ganz bequem per eMail.